Abstract

Variations in N-acylethanolamines (NAE) levels are associated with obesity and metabolic comorbidities. Their role in the gut remains unclear. Therefore, we generated a mouse model of inducible intestinal epithelial cell (IEC)-specific deletion of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD), a key enzyme involved in NAE biosynthesis (Napepld∆IEC). We discovered that Napepld∆IEC mice are hyperphagic upon first high-fat diet (HFD) exposure, and develop exacerbated obesity and steatosis. These mice display hypothalamic Pomc neurons dysfunctions and alterations in intestinal and plasma NAE and 2-acylglycerols. After long-term HFD, Napepld∆IEC mice present reduced energy expenditure. The increased steatosis is associated with higher gut and liver lipid absorption. Napepld∆IEC mice display altered gut microbiota. Akkermansia muciniphila administration partly counteracts the IEC NAPE-PLD deletion effects. In conclusion, intestinal NAPE-PLD is a key sensor in nutritional adaptation to fat intake, gut-to-brain axis and energy homeostasis and thereby constitutes a novel target to tackle obesity and related disorders.

Obesity is associated with altered N-acylethanolamine levels (NAE). Here the authors show that deletion of the gene encoding N-acylphosphatidylethanolamine phospholipase D, a key enzyme for NAE synthesis, in intestinal cells of mice leads to the development of obesity and hepatic steatosis via a mechanism involving the gut-brain axis.

Details

Title
Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis
Author
Everard Amandine 1 ; Plovier Hubert 1 ; Rastelli Marialetizia 1 ; Matthias, Van Hul 1 ; de Wouters d’Oplinter Alice 1 ; Geurts Lucie 1 ; Druart Céline 1 ; Robine Sylvie 2 ; Delzenne, Nathalie M 1 ; Muccioli, Giulio G 3   VIAFID ORCID Logo  ; de Vos Willem M 4   VIAFID ORCID Logo  ; Luquet Serge 5 ; Flamand, Nicolas 6 ; Di Marzo Vincenzo 7 ; Cani, Patrice D 1   VIAFID ORCID Logo 

 Université catholique de Louvain, Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Walloon Excellence in Life sciences and BIOtechnology (WELBIO), UCLouvain, Bruxelles, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X) 
 Institut Curie, CNRS, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384) 
 UCLouvain, Université catholique de Louvain, Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Bruxelles, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X) 
 Wageningen University, Laboratory of Microbiology, Wageningen, the Netherlands (GRID:grid.4818.5) (ISNI:0000 0001 0791 5666) 
 Sorbonne Paris Cité, BFA, UMR8251, CNRS, Université Paris Diderot, Paris, France (GRID:grid.4444.0) (ISNI:0000 0001 2112 9282) 
 Université Laval, Quebec Heart and Lung Institute Research Centre, G1V 0A6 Quebec City, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390) 
 Université Laval, Quebec Heart and Lung Institute Research Centre, G1V 0A6 Quebec City, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390); Université Laval, Institute of Nutrition and Functional Foods, G1V 0A6 Quebec City, Canada (GRID:grid.23856.3a) (ISNI:0000 0004 1936 8390); Consiglio Nazionale delle Ricerche, Endocannabinoid Research Group, Institute of Biomolecular Chemistry, 80078 Pozzuoli, Napoli, Italy (GRID:grid.5326.2) (ISNI:0000 0001 1940 4177) 
Publication year
2019
Publication date
Jan 2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2172175030
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.